Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.
about
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human seraCharacterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitopeLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsMaturation of the Human Papillomavirus 16 CapsidThe C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host InteractionEfficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions.Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.Characterization of a major neutralizing epitope on human papillomavirus type 16 L1L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidationHumoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccineEfficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants.Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16How will HPV vaccines affect cervical cancer?Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy.Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particlesDevelopment and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individualsNeutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.Genetic Diversity in the Major Capsid L1 Protein of HPV-16 and HPV-18 in the Netherlands.Multiscale simulation of microbe structure and dynamics.Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles.Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron MicroscopyCleavage of the HPV16 Minor Capsid Protein L2 during Virion Morphogenesis Ablates the Requirement for Cellular Furin during De Novo Infection.A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1Evidence for Placental HPV Infection in Both HIV Positive and Negative Women.A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody responseAmino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles.Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes.Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops.HPV entry into cells.Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses
P2860
Q24545868-CAC6654E-87B2-483F-A1B8-C60E399BC384Q24796150-21920823-E84A-47C1-A36E-B01705BDC5E0Q27013018-E6A8A79C-A138-4E89-AEEF-F781C8783BD3Q27684947-E1E503C8-C705-4CB7-A514-D7D547573FECQ27709061-F0B8A2CD-25D1-4AE0-B1C8-ECF611C4D319Q33652425-33C1CBCE-A673-4287-84D5-AA99AD9506E7Q33788885-A8DF82EF-2E63-4BEC-9FC0-002245857006Q33813986-B3A9057B-6586-4FB1-9521-5621F273BECBQ33839721-BDCAB22F-FEB9-4CF1-9D08-E0A6449D67DDQ33908917-CE68BC1B-D3C8-46D9-A715-641E9F95B3F7Q34032367-841A69D5-9D82-4409-9D15-0E1AFAFA51EAQ34074835-FB7E90F2-ADBF-4D41-B8FC-7D165A25B9C0Q34227402-F6C02439-68F8-4C30-B134-E0CC5C14BD6CQ34256293-06312C3F-294E-4F13-9746-9E4BC0F7515EQ34579346-E1A4A263-3B6E-48CA-90ED-E9077DA9641BQ34786808-A031FC13-C796-4D4C-AB1C-4F11D1E77051Q35079915-123DD2A5-1A31-4677-BBF4-9EF9E72F77EAQ35088658-6C5D1CA3-296A-478C-9B38-354BC7A217ADQ35155333-A428991F-A163-4B91-A3F9-F49163AFC7ECQ35235035-1CB54931-79F1-498A-AA47-441DD6CFB54FQ35605295-F0078042-66C4-4BCE-8FF7-824BAE3ECFEEQ35704086-A6151AB9-60F7-4D07-B77A-2878E0CBAFD7Q35869579-3C0F9104-E41E-4441-A1E1-76DA727442C9Q35947703-D3B5CF63-3009-4A89-8500-20FDFAFBBF27Q35987309-7BC6FD9D-014A-4559-9AC7-F077C6A9E6CDQ36058098-4BE3C380-199F-4E7D-96B3-A89413F9ED36Q36088309-E92FCCCD-2BEB-4DCD-9F6E-2677210CD86CQ36240497-3DEFC35D-5B8A-4ABC-8848-7EE1E93F0B36Q36281141-D4D9FFC3-1A5B-4A1C-834F-F8B85F701A92Q36333638-E1FDC28F-7FF2-4382-821D-CD6B71F09124Q36448778-7BF1AB6B-8A70-46B3-BEE5-F75296786D71Q36541188-4915D232-D625-4B72-9D92-E07D540FC836Q36558193-CF178F3F-6850-4188-A4DB-808D8C333E89Q36673310-3713DDDC-BCFB-49C4-9146-A0391BA1EBEEQ37162220-30731320-2DFE-49AD-BB2E-356CC9A0E67CQ37184404-A375A631-8850-4A5B-82CA-8BE7122353F2Q37219752-BC9F1F8C-88FB-4869-8E31-9CF6B31D915DQ37226543-BF0BB412-12C6-4433-B740-3D825F1AB1AFQ39320596-1478D3F3-D377-468F-867A-D3D30D0B6DD3Q39793237-FA02AEE4-6D5A-4A21-8159-DE93B8D543D5
P2860
Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Characterization of a human pa ...... ependent neutralizing epitope.
@ast
Characterization of a human pa ...... ependent neutralizing epitope.
@en
type
label
Characterization of a human pa ...... ependent neutralizing epitope.
@ast
Characterization of a human pa ...... ependent neutralizing epitope.
@en
prefLabel
Characterization of a human pa ...... ependent neutralizing epitope.
@ast
Characterization of a human pa ...... ependent neutralizing epitope.
@en
P2093
P2860
P1433
P1476
Characterization of a human pa ...... ependent neutralizing epitope.
@en
P2093
Armstrong A
Christensen ND
Hubbert NL
Kirnbauer R
Schiller JT
P2860
P304
P407
P577
1997-08-01T00:00:00Z